Cort
Phoenix Rising Founder
- Messages
- 7,392
This appears to be yet another study looking to test XMRV positive patients. Joliceur is doing this as well and if the Dusty Miller study gets going he'll be doing it to.
Dear SolveCFS BioBank participant,
Thank you for your continued participation in the SolveCFS BioBank. The CFIDS Association is establishing several new research collaborations and anticipates expanded interest in the BioBank during 2011. We are also in the final stages of migrating our clinical questionnaire to an online format and will be contacting BioBank participants to update their information when the on-line format is ready.
From time to time we will share information about other opportunities to participate in research studies that follow a different protocol than has been approved for the BioBank, like the one below. You can choose whether to follow-up on these opportunities or not. Whatever your decision is, it will not affect your current or future participation in the BioBank. Rest assured that we will not share any information about you with these research teams, and they will not disclose any information to us about your participation. All the privacy and confidentiality measures you count on will remain in place.
NEW STUDY RECRUITING DIAGNOSED CFS PATIENTS: As you may know, in late 2009 researchers reported the presence of a virus called XMRV in individuals with CFS. XMRV has also been reported in prostate cancer and has been found in a small number of healthy individuals as well. There is a growing body of research about XMRV, but there is presently no firm understanding about the role it may have in CFS or prostate cancer, or how the virus got into the human population. Laboratory studies have shown that the virus is difficult to find because it is present at low levels in the blood, and sensitive testing is necessary to detect it. For more information about XMRV, please visit the resource page on the CFIDS Association's web site at http://www.cfids.org/xmrv/default.asp.
Several teams of researchers at the National Institutes of Health (NIH) have been studying XMRV and have been working to develop new and more sensitive laboratory tests for it. One NIH team at the National Cancer Institute, has recently received approval to obtain samples directly from CFS patients. To be eligible for the study, you must have a diagnosis of CFS and must be under the care of a physician. You must also be willing and able to travel at your own expense to the NIH campus in Bethesda, Maryland for a screening evaluation.
The researchers are specifically trying to reach individuals who have already been tested for XMRV so they can compare the results of their new tests with the results obtained using other tests. People with positive or negative results will be eligible to participate. The NIH will share samples obtained in this study with other laboratories that have tests for XMRV. The goal is to determine which kind of test is best to detect XMRV. All participants will understand and give written consent before any samples are obtained, tested or shared. Participants have the right to withdraw from the study at any time.
Individuals who meet criteria for this study will make an appointment to receive a physical examination, routine laboratory tests and research tests at the NIH Clinical Center in Bethesda, Maryland. This study will not provide any medications. No new therapies, including antiretroviral therapies, will be tested in this study.
If you are interested in participating, please contact Dr. Frank Maldarelli, the study contact, at his office directly at (301) 435-8019 for more information.
Participation in this study will not be coordinated through the SolveCFS BioBank and any questions about it should be directed to the NIH.
With best wishes for health and progress in the new year,
Gloria E. Smith
SolveCFS BioBank Coordinator
The CFIDS Association of America
Our Mission:
For CFS to be widely understood, diagnosable,
curable and preventable.
Our Strategy:
To stimulate research aimed at the early detection, objective diagnosis and effective treatment of CFS through expanded public, private and commercial investment.
Our Core Values: